The CDC recommends that antiviral treatment be initiated within 48 hours of the onset of symptoms if possible. Early treatment can shorten the duration of illness and may reduce the risk for complications.
Initiate treatment with oseltamivir 75mg twice daily or zanamivir 10 mg (2 inhalations) twice daily.
The recommended duration of antiviral treatment for seasonal influenza is 5 days.
Currently, 2 commonly used classes of antiviral agents are approved for the prevention of and treatment for influenza: the M2 hydrogen ion channel blockers (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir and zanamivir). The M2 channel protein is found only on influenza A viruses. These agents have been proven to be safe and effective alone or in combination for the treatment of uncomplicated influenza in otherwise healthy individuals. Because circulating influenza A virus strains rapidly develop resistance to the adamantanes, amantadine and rimantidine are not recommended for antiviral treatment or chemoprophylaxis of influenza A.
In December 2012, the FDA approved oseltamivir for treatment but not prophylaxis of influenza in people aged 2 weeks and older. Zanamivir is not recommended for treatment or chemoprophylaxis in people with underlying respiratory disease (eg, asthma, chronic obstructive pulmonary disease).
CDC recommends antiviral chemoprophylaxis for a minimum of 2 weeks, and continuing up to 1 week after the last known case is identified. Antiviral chemoprophylaxis should be considered, especially for elderly long-term care facilities, for all exposed residents, including those who have received influenza vaccination.
Initiate treatment with oseltamivir 75mg twice daily or zanamivir 10 mg (2 inhalations) twice daily.
The recommended duration of antiviral treatment for seasonal influenza is 5 days.
Currently, 2 commonly used classes of antiviral agents are approved for the prevention of and treatment for influenza: the M2 hydrogen ion channel blockers (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir and zanamivir). The M2 channel protein is found only on influenza A viruses. These agents have been proven to be safe and effective alone or in combination for the treatment of uncomplicated influenza in otherwise healthy individuals. Because circulating influenza A virus strains rapidly develop resistance to the adamantanes, amantadine and rimantidine are not recommended for antiviral treatment or chemoprophylaxis of influenza A.
In December 2012, the FDA approved oseltamivir for treatment but not prophylaxis of influenza in people aged 2 weeks and older. Zanamivir is not recommended for treatment or chemoprophylaxis in people with underlying respiratory disease (eg, asthma, chronic obstructive pulmonary disease).
CDC recommends antiviral chemoprophylaxis for a minimum of 2 weeks, and continuing up to 1 week after the last known case is identified. Antiviral chemoprophylaxis should be considered, especially for elderly long-term care facilities, for all exposed residents, including those who have received influenza vaccination.
No comments:
Post a Comment